Telix Pharmaceuticals Limited TLPPF
Set alert
At close · Oct 29
- YTD
- +13.70%
- 1 year
- -20.00%
- Open
- 8.80
- Prev close
- 8.80
- Mkt cap
- 2.98B
- Vol
- 400
- Avg vol
- 1.82K
- EPS
- 0.10
- P/E
- 88.00
More statistics
- Low
- 8.80
- High
- 8.80
- Earnings
- Aug 20, 2026
News
1 month ago reuters.com
Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion
Australia's Telix Pharmaceuticals said on Monday it has agreed to acquire Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis.
6 months ago benzinga.com
Telix Seeks Reset With FDA Filing While Sales Growth Holds Steady
The agency assigned a PDUFA goal date of September 11.
6 months ago seekingalpha.com
Telix Pharmaceuticals: Solid Q1 As Pipeline And PSMA Franchise Drive Outlook
Telix Pharmaceuticals Limited delivered strong Q1 '26 results with $230M revenue, up 24% YoY, and reaffirmed FY26 guidance of $950–$970M, above consensus. Precision Medicine drove TLX growth, notably…
6 months ago benzinga.com
Why Is Telix Pharma Stock Soaring Tuesday?
Wedbush analyst David Nierengarten reiterated an Outperform rating on the stock and maintained a $22 price target, underscoring confidence in Telix's growth trajectory.
7 months ago defenseworld.net
Telix Pharmaceuticals (OTCMKTS:TLPPF) Shares Down 5.3% – Time to Sell?
Telix Pharmaceuticals Limited (OTCMKTS:TLPPF - Get Free Report)'s share price was down 5.3% on Wednesday. The stock traded as low as $8.85 and last traded at $8.85. Approximately 456 shares were…
7 months ago seekingalpha.com
Telix Pharmaceuticals Limited (TLX) Discusses Revenue Growth, Prostate Cancer Imaging Portfolio, and Expansion into Brain and Kidney Cancer Transcript
Telix Pharmaceuticals Limited (TLX) Discusses Revenue Growth, Prostate Cancer Imaging Portfolio, and Expansion into Brain and Kidney Cancer Transcript
7 months ago seekingalpha.com
Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript
Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript
8 months ago seekingalpha.com
Telix Pharmaceuticals Limited (TLX) Discusses Physician Perspectives on Innovations in PSMA PET CT Imaging for Prostate Cancer Transcript
Telix Pharmaceuticals Limited (TLX) Discusses Physician Perspectives on Innovations in PSMA PET CT Imaging for Prostate Cancer Transcript
8 months ago seekingalpha.com
Telix Pharmaceuticals: Scope Of Company Beyond Radio Antibody-Drug Conjugate TLX591-Tx
Telix Pharmaceuticals (TLX) maintains a "Buy" rating, driven by robust revenue growth and multiple late-stage oncology assets. TLX reported FY2025 revenue of $804 million, up 56% YoY, with Precision…
8 months ago seekingalpha.com
Telix Pharmaceuticals Limited (TLX) Q4 2025 Earnings Call Transcript
Telix Pharmaceuticals Limited (TLX) Q4 2025 Earnings Call Transcript
9 months ago benzinga.com
Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure
Telix Pharmaceuticals Limited (NASDAQ: TLX), a therapeutic and diagnostic radiopharmaceuticals company, on Tuesday reported its full-year revenue.
9 months ago seekingalpha.com
Telix Pharmaceuticals Limited (TLX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Telix Pharmaceuticals Limited (TLX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
9 months ago prnewswire.com
Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX
NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.
9 months ago prnewswire.com
Telix Pharmaceuticals Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX
NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.
10 months ago globenewswire.com
Deadline Alert: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming January 9, 2026 deadline to file a lead plaintiff motion in the class action filed on…
10 months ago prnewswire.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. Lawsuit - TLX
NEW YORK, Jan. 2, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.
10 months ago globenewswire.com
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Jan. 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited…
10 months ago globenewswire.com
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited…
10 months ago prnewswire.com
Class Action Filed Against Telix Pharmaceuticals Ltd. (TLX) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK , Dec. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.
10 months ago prnewswire.com
Shareholders that lost money on Telix Pharmaceuticals Ltd.(TLX) should contact Levi & Korsinsky about pending Class Action - TLX
NEW YORK , Dec. 23, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.